{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:18:46Z","timestamp":1761941926477,"version":"build-2065373602"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:00:00Z","timestamp":1661817600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.vhri.2022.08.003","type":"journal-article","created":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T05:00:58Z","timestamp":1663822858000},"page":"88-94","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Direct Medical Costs and Healthcare Resource Utilization of Treating Patients With Two Clinical Subtypes of Axial Spondyloarthritis in Colombia"],"prefix":"10.1016","volume":"32","author":[{"given":"Pedro","family":"Santos-Moreno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devian","family":"Parra-Padilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"G\u00f3mez-De la Rosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Carrasquilla-Sotomayor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Villarreal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David Scott","family":"Jervis-J\u00e1labe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nelson J.","family":"Alvis-Zakzuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.vhri.2022.08.003_bib1","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1136\/annrheumdis-2019-215142","article-title":"The world-wide burden of musculoskeletal diseases: a systematic analysis of the World Health Organization Burden of Diseases Database","volume":"78","author":"Sebbag","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.vhri.2022.08.003_bib2","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1136\/annrheumdis-2013-204627","article-title":"The global burden of rheumatoid arthritis: estimates from the Global Burden of Disease 2010 study","volume":"73","author":"Cross","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"10159","key":"10.1016\/j.vhri.2022.08.003_bib3","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","volume":"392","year":"2018","journal-title":"Lancet"},{"issue":"10089","key":"10.1016\/j.vhri.2022.08.003_bib4","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","article-title":"Axial spondyloarthritis","volume":"390","author":"Sieper","year":"2017","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.vhri.2022.08.003_bib5","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/RHU.0000000000000589","article-title":"Patient burden of axial spondyloarthritis","volume":"23","author":"Strand","year":"2017","journal-title":"J\u00a0Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.vhri.2022.08.003_bib6","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1186\/s12891-017-1693-z","article-title":"The relationship between demographic- and disease-related variables and health-related quality of life in patients with axial spondyloarthritis","volume":"18","author":"Rohde","year":"2017","journal-title":"BMC Musculoskelet Disord"},{"issue":"2","key":"10.1016\/j.vhri.2022.08.003_bib7","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001108","article-title":"Characteristics and burden of disease in patients with radiographic and non-radiographic axial spondyloarthritis: a comparison by systematic literature review and meta-analysis","volume":"5","author":"L\u00f3pez-Medina","year":"2019","journal-title":"RMD Open"},{"issue":"3","key":"10.1016\/j.vhri.2022.08.003_bib8","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/1756-185X.13777","article-title":"The direct and indirect costs of axial spondyloarthritis (axSpA) in Singapore","volume":"23","author":"Kwan","year":"2020","journal-title":"Int J Rheum Dis"},{"issue":"2","key":"10.1016\/j.vhri.2022.08.003_bib9","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s40744-016-0036-0","article-title":"Costs of drug therapy in patients\u00a0with ankylosing spondylitis in Brazil","volume":"3","author":"Machado","year":"2016","journal-title":"Rheumatol Ther"},{"issue":"8","key":"10.1016\/j.vhri.2022.08.003_bib10","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1136\/ard.62.8.732","article-title":"Direct costs of ankylosing spondylitis and its determinants: an analysis among three European countries","volume":"62","author":"Boonen","year":"2003","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.vhri.2022.08.003_bib11","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s00296-015-3236-y","article-title":"Direct and indirect costs associated with ankylosing spondylitis and related disease activity scores in Turkey","volume":"35","author":"Akko\u00e7","year":"2015","journal-title":"Rheumatol Int"},{"issue":"11","key":"10.1016\/j.vhri.2022.08.003_bib12","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1007\/s00296-018-4124-z","article-title":"Ankylosing spondylitis causes high burden to patients and the healthcare system: results from a German claims database analysis","volume":"38","author":"Kr\u00fcger","year":"2018","journal-title":"Rheumatol Int"},{"issue":"5","key":"10.1016\/j.vhri.2022.08.003_bib13","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/MAJ.0b013e3182514093","article-title":"Economic considerations of the treatment of ankylosing spondylitis","volume":"343","author":"Reveille","year":"2012","journal-title":"Am J Med Sci"},{"issue":"3","key":"10.1016\/j.vhri.2022.08.003_bib14","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.injr.2013.06.003","article-title":"Classification of spondyloarthritis: a journey well worth","volume":"8","author":"Malaviya","year":"2013","journal-title":"Indian J Rheumatol"},{"issue":"1","key":"10.1016\/j.vhri.2022.08.003_bib15","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s40744-020-00194-8","article-title":"Clinical, economic, and humanistic burden associated with delayed diagnosis of axial spondyloarthritis: a systematic review","volume":"7","author":"Yi","year":"2020","journal-title":"Rheumatol Ther"},{"issue":"1","key":"10.1016\/j.vhri.2022.08.003_bib16","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13075-017-1247-7","article-title":"Latin-American challenges and opportunities in rheumatology","volume":"19","author":"Rocha","year":"2017","journal-title":"Arthritis Res Ther"},{"issue":"suppl 1","key":"10.1016\/j.vhri.2022.08.003_bib17","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1007\/s10067-015-3016-9","article-title":"Proper management of rheumatoid arthritis in Latin America. What the guidelines say? [published correction appears in Clin Rheumatol. 2015;34(suppl 1):S57]","volume":"34","author":"Brenol","year":"2015","journal-title":"Clin Rheumatol"},{"issue":"suppl 2","key":"10.1016\/j.vhri.2022.08.003_bib19","first-page":"S144","article-title":"Sistema de salud de Colombia","volume":"53","author":"Guerrero","year":"2011","journal-title":"Salud Publ Mex"},{"author":"Lindstr\u00f6m","key":"10.1016\/j.vhri.2022.08.003_bib22"},{"key":"10.1016\/j.vhri.2022.08.003_bib23","first-page":"114","article-title":"Variability in resource consumption in patients with spondyloarthritis in Spain. Preliminary descriptive data from the emAR II study","volume":"8","author":"Jovani","year":"2012","journal-title":"ReumatolClin"},{"key":"10.1016\/j.vhri.2022.08.003_bib26","first-page":"31","article-title":"Frequency of health care resource utilization and direct medical costs associated with psoriatic arthritis in a Rheumatic Care Center in Colombia","volume":"11","author":"Santos-Moreno","year":"2021","journal-title":"Psoriasis (Auckl)"},{"issue":"2","key":"10.1016\/j.vhri.2022.08.003_bib29","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jval.2015.02.001","article-title":"Cost-effectiveness analysis alongside clinical trials II\u2014an ISPOR good research practices task force report","volume":"18","author":"Ramsey","year":"2015","journal-title":"Value Health"},{"issue":"8","key":"10.1016\/j.vhri.2022.08.003_bib30","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1002\/hec.1653","article-title":"Review of statistical methods for analysing healthcare resources and costs","volume":"20","author":"Mihaylova","year":"2011","journal-title":"Health Econ"},{"issue":"4","key":"10.1016\/j.vhri.2022.08.003_bib31","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1258\/1355819042250249","article-title":"Multiple regression of cost data: use of generalised linear models","volume":"9","author":"Barber","year":"2004","journal-title":"J\u00a0Health Serv Res Policy"},{"issue":"2","key":"10.1016\/j.vhri.2022.08.003_bib32","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.rbr.2015.06.002","article-title":"Indirect and direct costs of treating patients with ankylosing spondylitis in the Brazilian public health system","volume":"56","author":"Azevedo","year":"2016","journal-title":"Rev Bras Reumatol Engl Ed"},{"issue":"6","key":"10.1016\/j.vhri.2022.08.003_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2022.105420","article-title":"Tender to touch - prevalence and impact of concomitant fibromyalgia and enthesitis in spondyloarthritis: an ancillary analysis of the ASAS PerSpA study","volume":"89","author":"Fitzgerald","year":"2022","journal-title":"Joint Bone Spine"},{"issue":"suppl 4","key":"10.1016\/j.vhri.2022.08.003_bib34","doi-asserted-by":"crossref","first-page":"iv47","DOI":"10.1093\/rheumatology\/keaa246","article-title":"Prevalence and impact of comorbidities in axial spondyloarthritis: systematic review and meta-analysis","volume":"59","author":"Zhao","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.vhri.2022.08.003_bib35","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X211045263","article-title":"Distribution of comorbidities in spondyloarthritis with regard to the phenotype and psoriasis: data from the ASAS-COMOSPA study","volume":"13","author":"Puche-Larrubia","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"2","key":"10.1016\/j.vhri.2022.08.003_bib36","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2016-000259","article-title":"Costs of drugs for treatment of rheumatic diseases","volume":"2","author":"Westhovens","year":"2016","journal-title":"RMD Open"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109922001455?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109922001455?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:13:42Z","timestamp":1761941622000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109922001455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":29,"alternative-id":["S2212109922001455"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2022.08.003","relation":{},"ISSN":["2212-1099"],"issn-type":[{"type":"print","value":"2212-1099"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Direct Medical Costs and Healthcare Resource Utilization of Treating Patients With Two Clinical Subtypes of Axial Spondyloarthritis in Colombia","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2022.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Society for Health Economics and Outcomes Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}